CMX990
Based on 1 Customer Validation
CMX990 is a SARS-CoV-2 3CL protease inhibitor. The EC90s for inhibiting SARS-CoV-2 were 9.6 nM and 101 nM in human bronchial epithelial cells (HBECs) and HeLa-ACE2 cells, respectively. CMX990 has good ADME and pharmacokinetic properties.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 96.63%
- CAS. Nr.: 2882934-64-5
- Formel: C22H32F3N3O6
- Molecular Weight:491.50
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biologische Aktivität
Beschreibung
IC50 & Target
SARS-CoV-2[1]
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Epithelial cell | EC50 |
5.3 nM
Compound: CMX990
|
Antiviral activity against SARS-CoV-2 infected in human Primary bronchial epithelial cell assessed as inhibition of viral growth
Antiviral activity against SARS-CoV-2 infected in human Primary bronchial epithelial cell assessed as inhibition of viral growth
|
[PMID: 38335279] |
| HCT-8 | CC50 |
>30 μM
Compound: CMX990
|
Cytotoxicity against human HCT-8 cells incubated for 120 hrs by Cell-Titer Glo assay
Cytotoxicity against human HCT-8 cells incubated for 120 hrs by Cell-Titer Glo assay
|
[PMID: 38335279] |
| HeLa | CC50 |
>40 μM
Compound: CMX990
|
Cytotoxicity against human HeLa cells expressing ACE2 incubated for 120 hrs by Cell-Titer Glo assay
Cytotoxicity against human HeLa cells expressing ACE2 incubated for 120 hrs by Cell-Titer Glo assay
|
[PMID: 38335279] |
| MRC5 | CC50 |
>30 μM
Compound: CMX990
|
Cytotoxicity against human MRC5 cells incubated for 120 hrs by Cell-Titer Glo assay
Cytotoxicity against human MRC5 cells incubated for 120 hrs by Cell-Titer Glo assay
|
[PMID: 38335279] |
Chemical Information
-
CAS. Nr. 2882934-64-5
-
Appearance Solid
-
Molecular Weight 491.50
-
Formel C22H32F3N3O6
-
Color White to off-white
-
SMILES
O=C(N[C@H](C(COC(F)(F)F)=O)C[C@@H]1CCNC1=O)[C@@H]2CC3(CC3)CN2C([C@H](O)CC(C)C)=O
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Protokoll
-
Protocol for Pharmacokinetic Study
Pharmacokinetic studies quantify how an organism handles a drug over time through absorption, distribution, metabolism, and excretion, and the core experimental readout is the concentration-time profile of parent drug and, when relevant, metabolites in biological matrices such as plasma, whole blood, urine, bile, or tissue. Pharmacokinetic analysis links dose, route, exposure, clearance, half-life, distribution, bioavailability, and systemic exposure to drug efficacy and toxicity hypotheses rather than measuring a signaling pathway directly. The literature links pharmacokinetics to drug-development phenotypes by showing that drug metabolism and pharmacokinetics influence compound progression, exposure-response interpretation, safety margins, dosing strategy, and failure risk during discovery and development. DMPK science contributes to compound optimization by integrating physicochemical properties, in vitro metabolism, transporter behavior, in vivo exposure, and pharmacodynamic contex
Reinheit & Dokumentation
-
Data Sheet (270 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)